ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Collectively, these findings suggest that FAM167A and DSG1 are associated with BCR-ABL-independent TKI resistance in CML patients via activation of the noncanonical NF-κB pathway (Fig. 7C).